Chevy Chase Trust’s Ascentage Pharma AAPG Stock Holding History

Chevy Chase Trust’s Portfolio AAPG Stock Details AAPG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,753	Closed	-$227K	–	645
2025 Q2	$227K	Buy	+5,753	New	+$152K	﹤0.01%	624

Other funds holding AAPG

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return

Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return

NIM

NEOS Investment Management Westport, Connecticut $19.8B AUM 31.12% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Chevy Chase Trust's AAPG Position: Q3 2025 in Review

Chevy Chase Trust sold out of Ascentage Pharma (AAPG) in Q3 2025, closing a stake of 5,753 shares — an estimated $227K sold.

Chevy Chase Trust first reported a position in AAPG in Q2 2025 and held it in 1 quarter. The position peaked at $227K in Q2 2025. 14 funds tracked by Wall St. Rank hold AAPG as of Q3 2025.

Chevy Chase Trust reported no remaining Ascentage Pharma position as of Q3 2025 after selling out during the quarter.
Chevy Chase Trust sold 5,753 Ascentage Pharma shares in Q3 2025, an estimated $227K.
Chevy Chase Trust first reported a position in Ascentage Pharma in Q2 2025 and held it in 1 quarter.
Chevy Chase Trust's Ascentage Pharma position peaked at $227K in Q2 2025.
14 funds tracked by Wall St. Rank held Ascentage Pharma as of Q3 2025.

Based on Chevy Chase Trust's 13F filing for Q3 2025, filed 14 Nov 2025.